Canaccord analyst Kyle Mikson raised the firm’s price target on 10x Genomics to $70 from $65 and keeps a Buy rating on the shares. The firm said they remain bullish on the shares following a solid quarter, highlighted by strong Xenium demand, recognizing near-term macro headwinds exist.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TXG: